Erratum: Serum amyloid A and inflammation in diabetic kidney disease and podocytes (Laboratory Investigation (2014) DOI: 10.1038/labinvest.2014.163);Serum amyloid A and inflammation in diabetic kidney disease and podocytes

Laboratory Investigation

Volumn 95, Issue 3, 2015, Pages 250-262

  Anderberg, Robert J ^a,c   Meek, Rick L ^a   Hudkins, Kelly L ^b   Cooney, Sheryl K ^a   Alpers, Charles E ^b   LeBoeuf, Renee C ^b   Tuttle, Katherine R ^a,b  

^a Providence Medical Center   (United States)

^b UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^c SACRED HEART MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADVANCED GLYCATION END PRODUCT; COMPLEMENT COMPONENT C3; CXCL1 CHEMOKINE; CXCL2 CHEMOKINE; CXCL3 CHEMOKINE; EPITHELIAL DERIVED NEUTROPHIL ACTIVATING FACTOR 78; GRANULOCYTE COLONY STIMULATING FACTOR; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INDUCIBLE NITRIC OXIDE SYNTHASE; INTERLEUKIN 1; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; INTERLEUKIN 6; MONOCYTE CHEMOTACTIC PROTEIN 1; RANTES; SERUM AMYLOID A; TOLL LIKE RECEPTOR 5; ANTIOXIDANT; PYRROLIDINE DERIVATIVE; PYRROLIDINE DITHIOCARBAMIC ACID; RECOMBINANT PROTEIN; THIOCARBAMIC ACID DERIVATIVE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DIABETES CONTROL; DIABETIC NEPHROPATHY; GLOMERULUS FILTRATION RATE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INFLAMMATION; KIDNEY PARENCHYMA; MOUSE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PODOCYTE; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEINURIA; SIGNAL TRANSDUCTION; UPREGULATION; ANIMAL; ANTAGONISTS AND INHIBITORS; BLOOD; C57BL MOUSE; CELL CULTURE; DRUG EFFECTS; GENE EXPRESSION; GENETICS; INSULIN DEPENDENT DIABETES MELLITUS; KIDNEY; KIDNEY DISEASE; METABOLISM; PATHOLOGY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

ANIMALS; ANTIOXIDANTS; CELLS, CULTURED; DIABETES MELLITUS, TYPE 1; DIABETES MELLITUS, TYPE 2; DIABETIC NEPHROPATHIES; GENE EXPRESSION; HUMANS; IMMUNOHISTOCHEMISTRY; INFLAMMATION; KIDNEY; KIDNEY DISEASES; MICE, INBRED C57BL; NF-KAPPA B; PODOCYTES; PYRROLIDINES; RECOMBINANT PROTEINS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SERUM AMYLOID A PROTEIN; THIOCARBAMATES;

EID: 84938537932     PISSN: 00236837     EISSN: 15300307     Source Type: Journal    
DOI: 10.1038/labinvest.2015.38     Document Type: Erratum

References (55)

1. Adler AI, Stevens RJ, Manley SE, et al. Development and progression of nephropathy in type 2 diabetes: the United Kingdom Prospective Diabetes Study (UKPDS 64). Kidney Int 2003;63:225-232.
2. Afkarian M, Sachs MC, Kestenbaum B, et al. Kidney disease and increased mortality risk in type 2 diabetes. J Am Soc Nephrol 2013;24:302-308.
3. Danaei G, Finucane MM, Lu Y, et al. National, regional, and global trends in fasting plasma glucose and diabetes prevalence since 1980: systematic analysis of health examination surveys and epidemiological studies with 370 country-years and 2.7 million participants. Lancet 2011;378:31-40.
4. Tuttle KR. Linking metabolism and immunology: diabetic nephropathy is an inflammatory disease. J Am Soc Nephrol 2005;16:1537-1538.
5. Navarro-Gonzalez JF, Mora-Fernandez C, Muros de Fuentes M, et al. Inflammatory molecules and pathways in the pathogenesis of diabetic nephropathy. Nat Rev Nephrol 2011;7:327-340.
6. Kalousova M, Zima T, Tesar V, et al. Advanced glycation end products in clinical nephrology. Kidney Blood Press Res 2004;27:18-28.
7. Goldin A, Beckman JA, Schmidt AM, et al. Advanced glycation end products: sparking the development of diabetic vascular injury. Circulation 2006;114:597-605.
8. Basta G, Schmidt AM, De Caterina R. Advanced glycation end products and vascular inflammation: implications for accelerated atherosclerosis in diabetes. Cardiovasc Res 2004;63:582-592.
9. Thallas-Bonke V, Coughlan MT, Tan AL, et al. Targeting the AGE-RAGE axis improves renal function in the context of a healthy diet low in advanced glycation end-product content. Nephrology (Carlton) 2013;18:47-56.
10. Meek RL, LeBoeuf RC, Saha SA, et al. Glomerular cell death and inflammation with high-protein diet and diabetes. Nephrol Dial Transplant 2013;28:1711-1720.
11. Uhlar CM, Whitehead AS. Serum amyloid A, the major vertebrate acute-phase reactant. Eur J Biochem 1999;265:501-523.
12. Sipe J. Revised nomenclature for serum amyloid A (SAA). Nomenclature Committee of the International Society of Amyloidosis. Part 2. Amyloid 1999;6:67-70.
13. Meek RL, Benditt EP. Amyloid A gene family expression in different mouse tissues. J Exp Med 1986;164:2006-2017.
14. Kluve-Beckerman B, Drumm ML, Benson MD. Nonexpression of the human serum amyloid A three (SAA3) gene. DNA Cell Biol 1991;10:651-661.
15. Upragarin N, Landman WJ, Gaastra W, et al. Extrahepatic production of acute phase serum amyloid A. Histol Histopathol 2005;20:1295-1307.
16. Reigstad CS, Backhed F. Microbial regulation of SAA3 expression in mouse colon and adipose tissue. Gut Microbes 2010;1:55-57.
17. den Hartigh LJ, Wang S, Goodspeed L, et al. Deletion of serum amyloid a3 improves high fat high sucrose diet-induced adipose tissue inflammation and hyperlipidemia in female mice. PLoS One 2014; 9:e108564.
18. Yamamoto K, Migita S. Complete primary structures of two major murine serum amyloid A proteins deduced from cDNA sequences. Proc Natl Acad Sci USA 1985;82:2915-2919.
19. Connolly M, Marrelli A, Blades M, et al. Acute serum amyloid A induces migration, angiogenesis, and inflammation in synovial cells in vitro and in a human rheumatoid arthritis/SCID mouse chimera model. J Immunol 2010;184:6427-6437.
20. Vallon R, Freuler F, Desta-Tsedu N, et al. Serum amyloid A (apoSAA) expression is up-regulated in rheumatoid arthritis and induces transcription of matrix metalloproteinases. J Immunol 2001;166:2801-2807.
21. Meek RL, Urieli-Shoval S, Benditt EP. Expression of apolipoprotein serum amyloid A mRNA in human atherosclerotic lesions and cultured vascular cells: implications for serum amyloid A function. Proc Natl Acad Sci USA 1994;91:3186-3190.
22. Hua S, Song C, Geczy CL, et al. A role for acute-phase serum amyloid A and high-density lipoprotein in oxidative stress, endothelial dysfunction and atherosclerosis. Redox Rep 2009;14:187-196.
23. Yan SD, Zhu H, Zhu A, et al. Receptor-dependent cell stress and amyloid accumulation in systemic amyloidosis. Nat Med 2000;6: 643-651.
24. Okamoto H, Katagiri Y, Kiire A, et al. Serum amyloid A activates nuclear factor-kappaB in rheumatoid synovial fibroblasts through binding to receptor of advanced glycation end-products. J Rheumatol 2008;35: 752-756.
25. Cai H, Song C, Endoh I, et al. Serum amyloid A induces monocyte tissue factor. J Immunol 2007;178:1852-1860.
26. Saha SA, LaSalle BK, Clifton GD, et al. Modulation of advanced glycation end products by candesartan in patients with diabetic kidney disease-a dose-response relationship study. Am J Ther 2010;17:553-558.
27. Schmid H, Boucherot A, Yasuda Y, et al. Modular activation of nuclear factor-kappaB transcriptional programs in human diabetic nephropathy. Diabetes 2006;55:2993-3003.
28. Woroniecka KI, Park AS, Mohtat D, et al. Transcriptome analysis of human diabetic kidney disease. Diabetes 2011;60:2354-2369.
29. Tervaert TW, Mooyaart AL, Amann K, et al. Pathologic classification of diabetic nephropathy. J Am Soc Nephrol 2010;21:556-563.
30. Hudkins KL, Pichaiwong W, Wietecha T, et al. BTBR Ob/Ob mutant mice model progressive diabetic nephropathy. J Am Soc Nephrol 2010;21:1533-1542.
31. Alpers CE, Hudkins KL, Segerer S, et al. Localization of SPARC in developing, mature, and chronically injured human. Kidney Int 2002;62:2073-2086.
32. Wang A, Ziyadeh FN, Lee EY, et al. Interference with TGF-beta signaling by Smad3-knockout in mice limits diabetic glomerulosclerosis without affecting albuminuria. Am J Physiol Renal Physiol 2007;293:F1657-F1665.
33. Meek RL, Eriksen N, Benditt EP. Murine serum amyloid A3 is a high density apolipoprotein and is secreted by macrophages. Proc Natl Acad Sci USA 1992;89:7949-7952.
34. Shankland SJ, Pippin JW, Reiser J, et al. Podocytes in culture: past, present, and future. Kidney Int 2007;72:26-36.
35. Kumon Y, Suehiro T, Itahara T, et al. Serum amyloid A protein in patients with non-insulin-dependent diabetes mellitus. Clin Biochem 1994;27:469-473.
36. Dalla Vestra M, Mussap M, Gallina P, et al. Acute-phase markers of inflammation and glomerular structure in patients with type 2 diabetes. J Am Soc Nephrol 2005;16(Suppl 1):S78-S82.
37. Shvartsman SY, Hagan MP, Yacoub A, et al. Autocrine loops with positive feedback enable context-dependent cell signaling. Am J Physiol Cell Physiol 2002;282:C545-C559.
38. Banas MC, Banas B, Hudkins KL, et al. TLR4 links podocytes with the innate immune system to mediate glomerular injury. J Am Soc Nephrol 2008;19:704-713.
39. Brahler S, Ising C, Hagmann H, et al. Intrinsic proinflammatory signaling in podocytes contributes to podocyte damage and prolonged proteinuria. Am J Physiol Renal Physiol 2012;303:F1473-F1485.
40. Galkina E, Ley K. Leukocyte recruitment and vascular injury in diabetic nephropathy. J Am Soc Nephrol 2006;17:368-377.
41. Ruster C, Wolf G. The role of chemokines and chemokine receptors in diabetic nephropathy. Front Biosci 2008;13:944-955.
42. Mezzano S, Aros C, Droguett A, et al. NF-kappaB activation and overexpression of regulated genes in human diabetic nephropathy. Nephrol Dial Transplant 2004;19:2505-2512.
43. Geiser T, Dewald B, Ehrengruber MU, et al. The interleukin-8-related chemotactic cytokines GRO alpha, GRO beta, and GRO gamma activate human neutrophil and basophil leukocytes. J Biol Chem 1993;268:15419-15424.
44. Vieira S, Lemos H, Grespan R, et al. A crucial role for TNF-α in mediating neutrophil influx induced by endogenously generated or exogenous chemokines, KC/CXCL1 and LIX/CXCL5. Br J Pharmacol 2009;158:779-789.
45. Higurashi M, Ohya Y, Joh K, et al. Increased urinary levels of CXCL5, CXCL8 and CXCL9 in patients with Type 2 diabetic nephropathy. J Diabetes Complications 2009;23:178-184.
46. Van Damme J, Proost P, Lenaerts JP, et al. Structural and functional identification of two human, tumor-derived monocyte chemotactic proteins (MCP-2 and MCP-3) belonging to the chemokine family. J Exp Med 1992;176:59-65.
47. Schall TJ, Bacon K, Toy KJ, et al. Selective attraction of monocytes and T lymphocytes of the memory phenotype by cytokine RANTES. Nature 1990;347:669-671.
48. Chow FY, Nikolic-Paterson DJ, Ozols E, et al. Monocyte chemoattractant protein-1 promotes the development of diabetic renal injury in streptozotocin-treated mice. Kidney Int 2006;69:73-80.
49. Gu L, Hagiwara S, Fan Q, et al. Role of receptor for advanced glycation end-products and signalling events in advanced glycation endproduct-induced monocyte chemoattractant protein-1 expression in differentiated mouse podocytes. Nephrol Dial Transplant 2006;21: 299-313.
50. Han CY, Subramanian S, Chan CK, et al. Adipocyte-derived serum amyloid A3 and hyaluronan play a role in monocyte recruitment and adhesion. Diabetes 2007;56:2260-2273.
51. Trachtman H, Futterweit S, Pine E, et al. Chronic diabetic nephropathy: role of inducible nitric oxide synthase. Pediatr Nephrol 2002;17:20-29.
52. Moriwaki Y, Yamamoto T, Shibutani Y, et al. Elevated levels of interleukin-18 and tumor necrosis factor-[alpha] in serum of patients with type 2 diabetes mellitus: relationship with diabetic nephropathy. Metabolism 2003;52:605-608.
53. Starkey JM, Haidacher SJ, LeJeune WS, et al. Diabetes-induced activation of canonical and noncanonical nuclear factor-kB pathways in renal cortex. Diabetes 2006;55:1252-1259.
54. Breyer MD, Coffman TM, Flessner MF, et al. Diabetic nephropathy: a national dialogue. Clin J Am Soc Nephrol 2013;8:1603-1605.
55. Kim MH, de Beer MC, Wroblewski JM, et al. SAA does not induce cytokine production in physiological conditions. Cytokine 2013;61:506-512.